Ascletis Pharma Inc.

SEHK:1672 Stock Report

Market Cap: HK$3.0b

Ascletis Pharma Management

Management criteria checks 2/4

Ascletis Pharma's CEO is Jinzi Jason Wu, appointed in Apr 2013, has a tenure of 11.67 years. total yearly compensation is CN¥57.67M, comprised of 99.9% salary and 0.1% bonuses, including company stock and options. directly owns 57.06% of the company’s shares, worth HK$1.72B. The average tenure of the management team and the board of directors is 5.5 years and 6.7 years respectively.

Key information

Jinzi Jason Wu

Chief executive officer

CN¥57.7m

Total compensation

CEO salary percentage99.9%
CEO tenure11.7yrs
CEO ownership57.1%
Management average tenure5.5yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Oct 07
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03
What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13
Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27
Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Jinzi Jason Wu's remuneration changed compared to Ascletis Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥258m

Mar 31 2024n/an/a

-CN¥202m

Dec 31 2023CN¥58mCN¥58m

-CN¥145m

Sep 30 2023n/an/a

-CN¥194m

Jun 30 2023n/an/a

-CN¥243m

Mar 31 2023n/an/a

-CN¥279m

Dec 31 2022CN¥23mCN¥22m

-CN¥315m

Sep 30 2022n/an/a

-CN¥246m

Jun 30 2022n/an/a

-CN¥176m

Mar 31 2022n/an/a

-CN¥188m

Dec 31 2021CN¥20mCN¥20m

-CN¥199m

Sep 30 2021n/an/a

-CN¥234m

Jun 30 2021n/an/a

-CN¥269m

Mar 31 2021n/an/a

-CN¥239m

Dec 31 2020CN¥11mCN¥11m

-CN¥209m

Sep 30 2020n/an/a

-CN¥155m

Jun 30 2020n/an/a

-CN¥100m

Mar 31 2020n/an/a

-CN¥98m

Dec 31 2019CN¥11mCN¥11m

-CN¥96m

Compensation vs Market: Jinzi Jason's total compensation ($USD7.90M) is above average for companies of similar size in the Hong Kong market ($USD393.51K).

Compensation vs Earnings: Jinzi Jason's compensation has increased whilst the company is unprofitable.

CEO

Jinzi Jason Wu (60 yo)

11.7yrs

Tenure

CN¥57,668,000

Compensation

Dr. Jinzi Jason Wu Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScience Co., Ltd.a pharmace...

Leadership Team

NamePositionTenureCompensationOwnership
Jinzi Jason Wu
Founder11.7yrsCN¥57.67m57.06%
HK$ 1.7b
Hejingdao Wu
Senior VP of Operations & Executive Directorno dataCN¥2.85m0.12%
HK$ 3.6m
Yuemei Yan
Senior Vice President of Clinical Development Operations3.8yrsno datano data
Kristjan Gudmundsson
Senior Consultant & Head of Discovery11.6yrsno datano data
George Hill
Senior Consultant & Chief Medical Advisor7.3yrsno datano data
John Gargiulo
Chief Business Officer2.5yrsno datano data
Ming Fai Chung
Company Secretary2.3yrsno datano data

5.5yrs

Average Tenure

56yo

Average Age

Experienced Management: 1672's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jinzi Jason Wu
Founder10.8yrsCN¥57.67m57.06%
HK$ 1.7b
Hejingdao Wu
Senior VP of Operations & Executive Director6.8yrsCN¥2.85m0.12%
HK$ 3.6m
Jiong Gu
Independent Non-Executive Director6.7yrsCN¥385.00kno data
Yizhen Wei
Independent Non-Executive Director6.7yrsCN¥385.00kno data
Lin Hua
Independent Non-Executive Director6.7yrsCN¥385.00kno data

6.7yrs

Average Tenure

50yo

Average Age

Experienced Board: 1672's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 16:29
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascletis Pharma Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangChina Merchants Securities (HK) Co., Ltd
Mingrui WangEverbright Securities Co. Ltd.
Siao YeEverbright Securities Co. Ltd.